Sarilumab reduces disease activity in rheumatoid arthritis patients with inadequate response to janus kinase inhibitors or tocilizumab in regular care in Germany,
Rheumatology Advances in Practice, Volume 6, Issue 1, 2022, rkac002
https://doi.org/10.1093/rap/rkac002